scholarly journals Circulating Low Absolute CD4+ T Cell Counts May Predict Poor Prognosis in Extranodal NK/T-Cell Lymphoma Patients Treating with Pegaspargase-Based Chemotherapy

2019 ◽  
Vol 51 (1) ◽  
pp. 368-377 ◽  
Author(s):  
Ya-Ping Zhang ◽  
Run Zhang ◽  
Hua-Yuan Zhu ◽  
Li Wang ◽  
Yu-Jie Wu ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cd4 T Cell ◽  
Cell Counts ◽  
Nk T Cell

scholarly journals CIRCULATING LOW ABSOLUTE CD4+ T CELL COUNTS MAY PREDICT POOR PROGNOSIS IN PATIENTS WITH EXTRANODAL NK/T-CELL LYMPHOMA, NASAL TYPE

2017 ◽  
Vol 35 ◽  
pp. 390-391 ◽  
Author(s):  
W. Xu ◽  
Y. Zhang ◽  
J. Liang ◽  
L. Wang ◽  
H. Zhu ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Cd4 T Cell ◽  
Nasal Type ◽  
Cell Counts ◽  
Nk T Cell

scholarly journals Overexpression of MYC and BCL2 Predicts Poor Prognosis in Patients with Extranodal NK/T-cell Lymphoma, Nasal Type

2017 ◽  
Vol 8 (5) ◽  
pp. 793-800 ◽  
Author(s):  
Jing-hua Wang ◽  
Xi-wen Bi ◽  
Peng-fei Li ◽  
Zhong-jun Xia ◽  
Hui-qiang Huang ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Nk T Cell

Peripheral T-Cell Lymphoma-Unspecified (PTCL-U) and NK/T-Cell Lymphoma Showed a Significantly Poor Prognosis in a Randomized Controlled Trial (RCT) JCOG9002 with Multidrug Combination Chemotherapy for Aggressive Lymphoma.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 2465-2465
Author(s):  
Tomohiro Kinoshita ◽  
Tomomitsu Hotta ◽  
Taro Shibata ◽  
Kiyoshi Mukai ◽  
Motoko Yamaguchi ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
T Cell ◽  
Clinical Features ◽  
Combination Chemotherapy ◽  
Poor Prognosis ◽  
Who Classification ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Aggressive Lymphoma ◽  
Nk T Cell

Abstract PURPOSE: To elucidate clinical features of NHL subtyped with WHO classification, and to evaluate the prognostic impact of WHO classification on aggressive lymphoma treated in an RCT. METHODS: JCOG9002 was an RCT comparing two multidrug combination chemotherapy regimens, LSG9 and mLSG4 (Int J Hematol 80:341, 2004). Major eligibility criteria were; previously untreated patients with intermediate- or high-grade NHL on WF (ATL, LbL and CTCL were excluded); CS I to IV except CS I in GI, thyroid, orbit, or Waldeyer; age 15–69. Tissue specimens were centrally reviewed by six hematopathologists and classified according to WHO classification of lymphoid tumors. Overall survival (OAS) and complete response rate (%CR) of each WHO category were analyzed. Multivariate analyses of prognostic factors influencing OAS were conducted. RESULTS: A total of 447 patients were registered between 1991 and 1995, and the central pathological review was conducted on 404 patients. Characteristics of the 404 pts include median (range) age 56 (18–69) years; male/female 63/37%, CS I+II/III+IV 31/69%; LDH N/>N 51/49%; PS 0+1/2–4 78/22%; No. of extranodal sites 0–1/1< 77/23%; IPI L/LI/HI/H 40/27/20/12%. Major clinical features, OAS and %CR of major types according to WHO classification are summarized in Table 1. Twelve patients with FL (G1+2) were ineligible in this study but included. Clinical features, response to treatment and prognosis of each subtypes showed distinct patterns. Besides, we found that PTCL-U and NK/T-cell lymphoma showed lower CR rate and poorer OAS, and these features were quite different from other PTCL such as AILT or ALCL. Clinical features in other subtypes were similar to previous reports (Blood89: 3909, 1997; J Clin Oncol16: 2780, 1998). Cox regression analysis with IPI and WHO classification in 366 pts without missing value revealed that PTCL-U and NK/T-cell lymphoma were significant prognostic factors independent from IPI. Hazard ratios of these subgroups vs IPI low risk DLBCL group are 2.66 (95% confidence interval: 1.58–4.48) and 3.21 (1.40–7.37). CONCLUSIONS: Patients with aggressive lymphoma subtyped according to the WHO classification who were treated in an RCT showed distinctive clinical features. PTCL-U and NK/T-cell lymphoma showed a significantly poor prognosis independent from IPI, warranting further investigations focusing on these two subtypes. Table 1 No of cases (%) % male Median age % stage III or IV % IPI HI/H %5-yr OAS % CR *Pts with missing value are excluded from the denominator. Only major subtypes are included in this table. DLBCL 242 (59.9) 61 58 63 37 55 71 FL, all grades 37 (9.2) 70 55 68 15 76 70 MCL 15 (3.7) 60 57 87 20 53 73 MZL 9 (2.2) 56 51 71 0 89 67 AILT 22 (5.4) 77 58 100 67 67 73 PTCL-U 23 (5.7) 65 51 83 38 22 43 ALCL 10 (2.5) 70 50 70 33 70 70 NK/T 10 (2.5) 80 52 70 25 40 40

scholarly journals Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase

Oncotarget ◽  
2015 ◽  
Vol 6 (30) ◽  
pp. 30317-30326 ◽  
Author(s):  
Liang Wang ◽  
Hua Wang ◽  
Jing-hua Wang ◽  
Zhong-jun Xia ◽  
Yue Lu ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Post Treatment ◽  
T Cell Lymphoma ◽  
Early Relapse ◽  
Ebv Dna ◽  
Nk T Cell

CD56-negative extranodal NK/T cell lymphoma should be regarded as a distinct subtype with poor prognosis

Tumor Biology ◽  
2015 ◽  
Vol 36 (10) ◽  
pp. 7717-7723 ◽  
Author(s):  
Liang Wang ◽  
Zhao Wang ◽  
Zhong-jun Xia ◽  
Yue Lu ◽  
Hui-qiang Huang ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nk T Cell ◽  
Distinct Subtype

scholarly journals Genomic profiling of plasma circulating tumor DNA reveals genetics and residual disease in extranodal NK/T-cell lymphoma

2019 ◽  
Author(s):  
Qiong Li ◽  
Wei Zhang ◽  
Jiali Li ◽  
Jingkang Xiong ◽  
Jia Liu ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Residual Disease ◽  
Cell Lymphoma ◽  
Medical Center ◽  
Disease Status ◽  
Circulating Tumor Dna ◽  
T Cell Lymphoma ◽  
Nk T Cell ◽  
Tumor Dna

AbstractBackgroundExtranodal NK/T-cell lymphoma, nasal type (ENTKL), is an aggressive hematological malignancy with poor prognosis. Early detection of tumors at initial diagnosis or during routine surveillance is important for improving survival outcomes. Molecular profiling of circulating tumor DNA (ctDNA) is a promising noninvasive tool for monitoring disease status. Here, we investigated the feasible of ctDNA detection in ENTKL.MethodsPlasma ctDNA was assessment were based on blood specimens that were collected from 65 patients recently diagnosed with ENKTL at the hematology medical center of Xinqiao Hospital, longitudinal samples collected under chemotherapy also included. Gene mutation spectrum of ENKTL was analyzed via cancer personalized profiling sequencing (CAPP-Seq). This study is registered with ClinicalTrials.gov (ChiCTR1800014813)ResultsFrom February 2017 to September 2019, 65 patients were enrolled, we found that the most frequently mutated genes were KMT2D (23.1%), APC (12.3%), ATM (10.8%), ASXL3 (9.2%), JAK3 (9.2%), SETD2 (9.2%), TP53 (9.2%), NOTCH1 (7.7%). The mutation frequencies of KMT2D was significantly higher in stage III-IV, and mutations in KMT2D, ASXL3 and JAK3 were significantly correlated with the metabolic tumor burden of the patients. Compared with tumor tissue DNA, ctDNA profiling showed good concordance. Serial ctDNA analysis showed that treatment with chemotherapy could decrease the number and mutation allele frequency of genes. Compared with PET/CT, ctDNA has more advantages for tracking residual disease in patients. In addition, we also found that mutated KMT2D predicted poor prognosis in patients.ConclusionCollectively, our results provide evidence that ctDNA may serve as a novel precision medicine biomarker in ENKTL.

scholarly journals High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients

Oncotarget ◽  
2016 ◽  
Vol 7 (22) ◽  
pp. 33035-33045 ◽  
Author(s):  
Hua Wang ◽  
Liang Wang ◽  
Wen-Jian Liu ◽  
Zhong-Jun Xia ◽  
Hui-Qiang Huang ◽  
...  
Keyword(s):  
Cell Death ◽  
T Cell ◽  
Programmed Cell Death ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
Serum Levels ◽  
Post Treatment ◽  
T Cell Lymphoma ◽  
Early Relapse ◽  
Nk T Cell

CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type

2015 ◽  
Vol 94 (8) ◽  
pp. 1381-1388 ◽  
Author(s):  
Liang Wang ◽  
Hua Wang ◽  
Peng-fei Li ◽  
Yue Lu ◽  
Zhong-jun Xia ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nasal Type ◽  
Cd38 Expression ◽  
Nk T Cell ◽  
Therapy Target

High numbers of CD68+ tumor-associated macrophages correlate with poor prognosis in extranodal NK/T-cell lymphoma, nasal type

2015 ◽  
Vol 94 (9) ◽  
pp. 1535-1544 ◽  
Author(s):  
Hua Wang ◽  
Pengfei Li ◽  
Liang Wang ◽  
Zhongjun Xia ◽  
HuiQiang Huang ◽  
...  
Keyword(s):  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Tumor Associated Macrophages ◽  
Nasal Type ◽  
Nk T Cell

scholarly journals Downregulation of miR-15a due to LMP1 promotes cell proliferation and predicts poor prognosis in nasal NK/T-cell lymphoma

2013 ◽  
Vol 89 (1) ◽  
pp. 25-33 ◽  
Author(s):  
Yuki Komabayashi ◽  
Kan Kishibe ◽  
Toshihiro Nagato ◽  
Seigo Ueda ◽  
Miki Takahara ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
T Cell ◽  
Poor Prognosis ◽  
Cell Lymphoma ◽  
T Cell Lymphoma ◽  
Nk T Cell
Sign in / Sign up

Export Citation Format

Share Document